RAPP

Rapport Therapeutics

28.93 USD
+2.05
7.63%
At close Updated Oct 31, 4:00 PM EDT
Pre-market
After hours
28.93
0.00
0%
1 day
7.63%
5 days
10.46%
1 month
-2.59%
3 months
101.46%
6 months
152.66%
Year to date
57.31%
1 year
17.94%
5 years
39.09%
10 years
39.09%
 

About: Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Employees: 69

0
Funds holding %
of 7,505 funds
0
Analysts bullish %
of 2 analysts
Positive news %
of articles
Price charts implemented using Lightweight Charts™